secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-208910
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q1 total revenue $90.2M (+15% YoY); Furoscix adds $15.5M; cash $134M
-----------------------------------------------------------------------------

- Total revenue $90.2M (+15% YoY); royalties from Tyvaso DPI up 9% to $32.7M.
- Furoscix net sales $15.5M (first full Q1 post-scPharma acquisition); Afrezza $15.3M (+3%).
- SG&A surged 116% to $54.1M driven by launch prep for Afrezza pediatric and Furoscix ReadyFlow.
- Cash and investments $134M; settled $36.3M convertible notes for $35.5M cash + 569K shares.
- Key PDUFA dates: Afrezza pediatric May 29; Furoscix Autoinjector July 26; nintedanib DPI Phase 2 enrollment Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/0001193125-26-208910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-208910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer